Tempest Therapeutics Inc (TPST)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.64M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tempest Therapeutics Inc (TPST) Stock Forecast
Analysts expect Tempest Therapeutics (TPST) to earn -$2.85 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.90.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$2.85
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.90
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.85 | -$2.85 to -$2.85 | 1 |
| Dec 31, 2027 | -$0.90 | -$0.90 to -$0.90 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.30 | N/A | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.85 | -$1.34 | -$1.34 | -$1.34 | -$1.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.90 | -$1.21 | -$1.21 | -$1.21 | -$1.21 | N/A |
Frequently Asked Questions About TPST
What is the TPST stock forecast?
Consensus analyst estimates put Tempest Therapeutics's EPS at -$2.85 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from TPST next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.85, with estimates from -$2.85 to -$2.85 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.90, with estimates from -$0.90 to -$0.90 from 1 analyst.
How many analysts cover TPST?
1 analyst estimates EPS for Tempest Therapeutics for the fiscal year ending Dec 31, 2026.
TPST pages: Overview, Earnings, Forecast, Financials, Competitors